Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection.
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study
Marchetti, Silvia;Rugge, Massimo;Fassan, Matteo;
2017
Abstract
Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Functional imaging ....pdf
accesso aperto
Tipologia:
Published (publisher's version)
Licenza:
Accesso gratuito
Dimensione
2.71 MB
Formato
Adobe PDF
|
2.71 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
